SCHEMBL1000293

SCHEMBL1000293

CN(C)C(=O)c1csc(-c2ccc(Br)cc2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.64
HDAC8 Q9BY41 2/20 0.64
HDAC6 Q9UBN7 2/20 0.64
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 3/20 0.51
HSD17B1 P14061 1/20 0.51
HSD17B2 P37059 1/20 0.51
RAB9A P51151 4/20 0.48
NPC1 O15118 2/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
TLR7 Q9NYK1 1/20 0.44
STS P08842 1/20 0.44
CYP19A1 P11511 1/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12925917 0.82 HSD17B1 (0.49) HDAC1HDAC8HDAC6ALDH1A1HSD17B1
SCHEMBL3461226 0.82 HSD17B1 (0.48) HDAC1HDAC8HDAC6ALDH1A1HSD17B1
SCHEMBL2554731 0.81 HDAC1 (0.71) HDAC1HDAC8HDAC6MEN1KMT2A
SCHEMBL999473 0.80 HDAC1 (0.69) HDAC1HDAC8HDAC6MEN1KMT2A
SCHEMBL12469791 0.79 HSD17B1 (0.46) HDAC1HDAC8HDAC6ALDH1A1HSD17B1
SCHEMBL12278085 0.79 HDAC1 (0.68) HDAC1HDAC8HDAC6MEN1KMT2A
SCHEMBL31553238 0.77 HDAC1 (0.39) HDAC1HDAC8HDAC6ALDH1A1HSD17B1
SCHEMBL12471487 0.76 HSD17B1 (0.46) MEN1KMT2AALDH1A1HSD17B1HSD17B2
SCHEMBL15849569 0.76 ALDH1A1 (0.58) MEN1KMT2AALDH1A1HSD17B1HSD17B2
SCHEMBL2552079 0.76 HDAC6 (0.78) HDAC1HDAC8HDAC6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7867980-B2 Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-11 US disclosed
US-20100184746-A1 LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD 2010-07-22 US disclosed
EP-2166015-A1 LINCOSAMIDE DERIVATIVE, AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT Meiji Seika Kaisha Ltd. (JP) 2010-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184746-A1 LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT SIRT6, LAS1L, MRPS18A HDAC1 14/4885HDAC8 143/4885HDAC6 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.